Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965788 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL14893577 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL14591344 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL8074255 | 0.80 | MTNR1A (0.73) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL14904932 | 0.78 | MTNR1A (0.50) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL1962875 | 0.77 | MTNR1A (0.40) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL3682479 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BEPHX2DRD2CA1 | |
| SCHEMBL29565539 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BEPHX2DRD2CA1 | |
| SCHEMBL20558275 | 0.75 | MTNR1A (0.49) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL1963207 | 0.71 | CA1 (0.59) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
| US-7902236-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | US | disclosed |
| US-7504520-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | MTNR1A 32/4885MTNR1B 51/4885CYP1A2 1044/4885 |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | MTNR1A 32/4885MTNR1B 51/4885CYP1A2 1044/4885 |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | MTNR1A 32/4885MTNR1B 51/4885CYP1A2 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.